MEI Pharma (MEIP) Revenue & Revenue Breakdown
MEI Pharma Revenue Highlights
Latest Revenue (Y)
$65.30M
MEI Pharma Revenue by Period
MEI Pharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $65.30M | 33.76% |
| 2023-06-30 | $48.82M | 19.95% |
| 2022-06-30 | $40.70M | 59.38% |
| 2021-06-30 | $25.54M | -11.68% |
| 2020-06-30 | $28.91M | 488.26% |
| 2019-06-30 | $4.92M | 203.02% |
| 2018-06-30 | $1.62M | -93.02% |
| 2017-06-30 | $23.25M | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2011-06-30 | - | -100.00% |
| 2010-06-30 | $84.00K | -63.16% |
| 2009-08-28 | $228.00K | -66.17% |
| 2008-09-03 | $674.00K | 4.50% |
| 2007-06-30 | $645.00K | -637.50% |
| 2006-06-30 | $-120.00K | -138.96% |
| 2005-06-30 | $308.00K | 59.59% |
| 2004-06-30 | $193.00K | 33.10% |
| 2003-06-30 | $145.00K | 1971.43% |
| 2002-06-30 | $7.00K | - |
MEI Pharma generated $65.30M in revenue during NA 2024, up 33.76% compared to the previous quarter, and up 1328.52% compared to the same period a year ago.
MEI Pharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2023-09-30 | $65.30M | 4381.61% |
| 2023-06-30 | $1.46M | -75.28% |
| 2023-03-31 | $5.89M | -81.99% |
| 2022-12-31 | $32.73M | 274.97% |
| 2022-09-30 | $8.73M | -23.51% |
| 2022-06-30 | $11.41M | 17.74% |
| 2022-03-31 | $9.69M | -46.80% |
| 2021-12-31 | $18.22M | 36.12% |
| 2021-09-30 | $13.39M | 32.33% |
| 2021-06-30 | $10.12M | 318.36% |
| 2021-03-31 | $2.42M | -73.62% |
| 2020-12-31 | $9.17M | 139.10% |
| 2020-09-30 | $3.83M | -84.97% |
| 2020-06-30 | $25.50M | 1950.16% |
| 2020-03-31 | $1.24M | 23.41% |
| 2019-12-31 | $1.01M | -12.88% |
| 2019-09-30 | $1.16M | 2.39% |
| 2019-06-30 | $1.13M | -9.53% |
| 2019-03-31 | $1.25M | -39.01% |
| 2018-12-31 | $2.05M | 319.67% |
| 2018-09-30 | $488.00K | -10.95% |
| 2018-06-30 | $548.00K | 26.56% |
| 2018-03-31 | $433.00K | 20.95% |
| 2017-12-31 | $358.00K | 26.50% |
| 2017-09-30 | $283.00K | -36.97% |
| 2017-06-30 | $449.00K | -90.03% |
| 2017-03-31 | $4.50M | -73.81% |
| 2016-12-31 | $17.20M | 1469.25% |
| 2016-09-30 | $1.10M | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | -100.00% |
| 2010-09-30 | $71.00K | 343.75% |
| 2010-06-30 | $16.00K | -15.79% |
| 2010-03-31 | $19.00K | -17.39% |
| 2009-12-31 | $23.00K | -11.54% |
| 2009-09-30 | $26.00K | -3.70% |
| 2009-06-30 | $27.00K | -6.90% |
| 2009-03-31 | $29.00K | -61.84% |
| 2008-12-31 | $76.00K | -20.83% |
| 2008-09-30 | $96.00K | 4.35% |
| 2008-06-30 | $92.00K | -38.26% |
| 2008-03-31 | $149.00K | - |
MEI Pharma generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
MEI Pharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CTMX | CytomX Therapeutics | $101.21M | $25.11M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| MEIP | MEI Pharma | $65.30M | - |
| OCUL | Ocular Therapeutix | $58.44M | $14.71M |
| HOOK | HOOKIPA Pharma | $20.13M | - |
| ASMB | Assembly Biosciences | $7.16M | $5.79M |
| KZR | Kezar Life Sciences | $7.00M | - |
| MGTA | Dianthus Therapeutics | $314.00K | $72.00K |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ZURA | Zura Bio | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| TIL | Instil Bio | - | - |
| REVB | Revelation Biosciences | - | - |
| NLTX | Neurogene | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ACHL | Achilles Therapeutics | - | - |
| VINC | Vincerx Pharma | - | - |
| ATXI | Avenue Therapeutics | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| RNAZ | TransCode Therapeutics | - | - |
MEIP Revenue FAQ
What is MEI Pharma’s yearly revenue?
MEI Pharma's yearly revenue for 2024 was $65.3M, representing an increase of 33.76% compared to 2023. The company's yearly revenue for 2023 was $48.82M, representing an increase of 19.95% compared to 2022. MEIP's yearly revenue for 2022 was $40.7M, representing an increase of 59.38% compared to 2021.
What is MEI Pharma’s quarterly revenue?
MEI Pharma's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). MEIP's quarterly revenue for Q1 2024 was $65.3M, a 4381.61% increase from the previous quarter (Q4 2023), and a 647.96% increase year-over-year (Q1 2023).
What is MEI Pharma’s revenue growth rate?
MEI Pharma's revenue growth rate for the last 3 years (2022-2024) was 60.45%, and for the last 5 years (2020-2024) was 125.84%.